filmov
tv
Psyched Wellness 90-day oral toxicity study is 'big turning point' for the company
Показать описание
Psyched Wellness Ltd (CSE:PSYC) (OTCQB:PSYCF) (FRA:5U9) CEO Jeff Stevens tells Proactive it has kicked off its next preclinical study of AME-1, its proprietary Amanita muscaria extract.
Stevens says the 90-day oral toxicity study is 'big turning point' for the company, as once results are received for both its 14-day and 90-day study, the specific dose range will allow it to move to the next phase of looking at product formulation.
Stevens says the 90-day oral toxicity study is 'big turning point' for the company, as once results are received for both its 14-day and 90-day study, the specific dose range will allow it to move to the next phase of looking at product formulation.
0:03:54
0:02:51
0:03:54
0:00:35
0:01:08
0:00:29
0:01:46
0:00:51
0:25:33
0:03:44
0:37:18
0:04:14
0:22:45
0:02:00
0:03:14
0:26:20
0:04:31
0:03:02
0:01:39
0:03:26
0:14:27
0:02:59
0:06:35
0:01:25